{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:40:14Z","timestamp":1787020814309,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Chemistry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Ipratropium bromide (IPR) and fenoterol hydrobromide (FEN) have recently been combined in a promising inhaler to treat two prevalent inflammatory illnesses of the airways: bronchial asthma and chronic obstructive pulmonary disease (COPD). The necessity for a single, sensitive, and trustworthy analytical approach to cover the diverse and necessary tests of in-vitro and in-vivo studies is greatly grown with the rising production of new fixed combinations. Two novel, selective and environmentally friendly LC techniques were developed in order to guarantee precise measurement of IPR and FEN in their challenging formulation. The initial technique involved high-performance thin-layer chromatography (HPTLC) in conjunction with densitometric quantification. Chromatographic separation was attained on HPTLC plates utilizing ethyl acetate - ethanol - acetic acid (5.0:5.0:0.1, by volume) as a developing system. Densitometric quantification of the separated bands was carried out at 220.0\u00a0nm over concentration ranges of 0.50\u201315.0\u00a0\u00b5g\/band for IPR and 0.50\u201312.0\u00a0\u00b5g\/band for FEN. High-performance liquid chromatography (HPLC) paired with diode array detection (DAD) was the core of the second technique. The optimized separation was achieved on a Zorbax SB C\n                    <jats:sub>18<\/jats:sub>\n                    (150\u2009\u00d7\u20094.6\u00a0mm, 5\u00a0\u03bcm) column with a combination of 10.0 mM potassium dihydrogen orthophosphate, pH 5.0\u2009\u00b1\u20090.1, adjusted with o-phosphoric acid and methanol (70:30, v\/v) as the mobile phase and pumped at flow rate of 1.0 mL\/min. The peaks were monitored at 220.0\u00a0nm using diode array detection, achieving linearity range of 5.0\u2013200.0\u00a0\u00b5g\/mL for both drugs. The ICH criteria have been verified and both methods have been confirmed to be valid, and successfully applied for assay the cited drugs in the Atrovent\n                    <jats:sup>\u00ae<\/jats:sup>\n                    comp HFA metered dose inhaler as well as delivered dose uniformity testing of the final product. Finally, whiteness appraisal and several state-of-the-art green evaluation metrics were applied to evaluate the sustainability of the proposed methods. The suggested approaches produced promising results and are the first simple and sustainable methodologies for the simultaneous quantification of both drugs in different real samples, all of which strongly suggest their application in quality control laboratories.\n                  <\/jats:p>","DOI":"10.1186\/s13065-024-01265-5","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T08:22:34Z","timestamp":1724746954000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Chromatographic fingerprinting of ipratropium and fenoterol in their novel co-formulated inhaler treating major respiratory disorders; application to delivered dose uniformity testing along with greenness and whiteness assessment"],"prefix":"10.1186","volume":"18","author":[{"given":"Salma N.","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samah S.","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed S.","family":"Fayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoda M.","family":"Marzouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,27]]},"reference":[{"key":"1265_CR1","doi-asserted-by":"crossref","unstructured":"Turner RM, DePietro M, Ding B. Overlap of asthma and chronic obstructive pulmonary disease in patients in the United States: analysis of prevalence, features, and subtypes. JMIR Public Health Surveill. 2018;4(8).","DOI":"10.2196\/preprints.9930"},{"key":"1265_CR2","doi-asserted-by":"publisher","first-page":"3546","DOI":"10.1172\/JCI36130","volume":"118","author":"PJ Barnes","year":"2008","unstructured":"Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest. 2008;118:3546\u201356.","journal-title":"J Clin Invest"},{"key":"1265_CR3","doi-asserted-by":"crossref","unstructured":"K\u00e4ssner F, Hodder R, Bateman ED. A Review of Ipratropium Bromide\/ Fenoterol Hydrobromide (Berodual \u00ae) Delivered Via Respimat \u00ae Soft Mist\u2122 Inhaler in Patients with Asthma and Chronic Obstructive Pulmonary Disease. Vol. 64, Drugs. 2004.","DOI":"10.2165\/00003495-200464150-00005"},{"key":"1265_CR4","doi-asserted-by":"crossref","unstructured":"Salama RO, Young PM, Rogueda P, Lallement A, Iliev I, Traini D. Advances in drug delivery: is triple therapy the future for the treatment of chronic obstructive pulmonary disease? 12, Expert Opinion on Pharmacotherapy. 2011. p. 1913\u201332.","DOI":"10.1517\/14656566.2011.589837"},{"issue":"1","key":"1265_CR5","doi-asserted-by":"publisher","first-page":"S104","DOI":"10.1067\/mai.2000.106636","volume":"106","author":"T Katsunuma","year":"2000","unstructured":"Katsunuma T, Fujita K, Mak JCW, Barnes PJ, Ueno K, Iikura Y. \u03b2-Adrenergic agonists and bronchial hyperreactivity: role of \u03b22- adrenergic and tachykinin neurokinin-2 receptors. J Allergy Clin Immunol. 2000;106(1):S104\u20138.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"1265_CR6","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/0731-7085(94)E0006-M","volume":"12","author":"GA Jacobson","year":"1994","unstructured":"Jacobson GA, Peterson GM. High-performance liquid chromatographic assay for the simultaneous determination of ipratropium bromide, fenoterol, salbutamol and terbutaline in nebulizer solution. J Pharm Biomed Anal. 1994;12(6):825\u201332.","journal-title":"J Pharm Biomed Anal"},{"key":"1265_CR7","doi-asserted-by":"crossref","unstructured":"Bryant DH. Nebulized ipratropium bromide in the treatment of acute asthma. Chest. 1985;88(1).","DOI":"10.1378\/chest.88.1.24"},{"key":"1265_CR8","doi-asserted-by":"crossref","unstructured":"O\u2019Driscoll BR, Horsley MG, Taylor RJ, Chambers DK, Bernstein A. Nebulized Salbutamol With and Without Ipratropium Bromide in Acute Airflow Obstruction. Lancet. 1989;333(8652).","DOI":"10.1016\/S0140-6736(89)90126-8"},{"key":"1265_CR9","doi-asserted-by":"crossref","unstructured":"Donohue JF. Combination therapy for chronic obstructive pulmonary disease: Clinical aspects. In: Proceedings of the American Thoracic Society. 2005. pp. 272\u201381.","DOI":"10.1513\/pats.200505-047SR"},{"key":"1265_CR10","doi-asserted-by":"publisher","first-page":"211","DOI":"10.58837\/CHULA.CMJ.65.2.15","volume":"65","author":"K Kawkitinarong","year":"2021","unstructured":"Kawkitinarong K, Ananpipatkul A, Sae-Eao N, Asawawichienchinda T, Sirichana W. Effects of fenoterol\/ipratropium bromide on FEV1 and hyperinflation in Thai COPD patients. Chulalongkorn Med J Apr. 2021;65:211\u20138.","journal-title":"Chulalongkorn Med J Apr"},{"key":"1265_CR11","doi-asserted-by":"publisher","unstructured":"Huhti E, Poukkula A. Comparison of Fenoterol, Ipratropium Bromide, and Their Combination in Patients with Asthma or Chronic Airflow Obstruction. Respiration [Internet]. 1986 Feb 1 [cited 2023 Sep 18];50(Suppl. 2):298\u2013301. https:\/\/doi.org\/10.1159\/000195150","DOI":"10.1159\/000195150"},{"issue":"4","key":"1265_CR12","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1208\/s12249-013-0024-4","volume":"14","author":"J Ninbovorl","year":"2013","unstructured":"Ninbovorl J, Sawatdee S, Srichana T. Factors affecting the stability and performance of ipratropium bromide; fenoterol hydrobromide pressurized-metered dose inhalers. AAPS PharmSciTech. 2013;14(4):1294\u2013302.","journal-title":"AAPS PharmSciTech"},{"key":"1265_CR13","doi-asserted-by":"crossref","unstructured":"Anastas P, Eghbali N. Green Chemistry: principles and practice. Chem Soc Rev. 2010;39(1).","DOI":"10.1039\/B918763B"},{"key":"1265_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-007-7735-4","volume-title":"Green chromatographic techniques: separation and purification of organic and inorganic analytes","author":"MA Inamuddin","year":"2014","unstructured":"Inamuddin MA. Green chromatographic techniques: separation and purification of organic and inorganic analytes. Volume 9789400777354. Green Chromatographic Techniques: Separation and Purification of Organic and Inorganic Analytes; 2014."},{"key":"1265_CR15","doi-asserted-by":"crossref","unstructured":"Fayed AS, Boltia SA, Musaed A, Hegazy MA. Selective quantitation of co-formulated ternary mixture in the presence of potential impurities by liquid chromatographic methods. J Pharm Biomed Anal. 2020;177.","DOI":"10.1016\/j.jpba.2019.112821"},{"key":"1265_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.chroma.2013.07.099","volume":"1307","author":"J P\u0142otka","year":"2013","unstructured":"P\u0142otka J, Tobiszewski M, Sulej AM, Kupska M, G\u00f3recki T, Namie\u015bnik J. J Chromatogr A. 2013;1307:1\u201320. Green chromatography.","journal-title":"J Chromatogr A"},{"key":"1265_CR17","doi-asserted-by":"crossref","unstructured":"Abou Al-Alamein AM, Abd El-Rahman MK, Abdel-Moety EM, Fawaz EM. Green HPTLC-densitometric approach for simultaneous determination and impurity- profiling of ebastine and phenylephrine hydrochloride. Microchem J. 2019;147.","DOI":"10.1016\/j.microc.2019.04.043"},{"key":"1265_CR18","unstructured":"British Pharmacopeia. vol. II, The Stationary Office, London, 2022."},{"key":"1265_CR19","unstructured":"Committee for Medicinal Products for Human Use (CHMP), Guideline on the Pharmaceutical Quality of Inhalation and Nasal Products, in: EMEA\/CHMP\/QWP\/49313\/2005. 2006. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-pharmaceutical-quality-inhalation-and-nasal-products_en.pdf"},{"key":"1265_CR20","unstructured":"FDA, Guidance for Industry. (2018). Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Products-Quality Considerations. US department of health and human services, Food and Drug Administration, Center for Drug Evaluation and Research, 2018. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/metered-dose-inhaler-mdi-and-dry-powder-inhaler-dpi-drug-products-quality-considerations"},{"key":"1265_CR21","doi-asserted-by":"crossref","unstructured":"Marzouk HM, Ibrahim EA, Hegazy MA, Saad SS. Greenness profile assessment of selective liquid chromatographic methods for determination of a quaternary antimigraine combination along with three of their related official impurities. Biomed Chromatogr. 2021;35(9).","DOI":"10.1002\/bmc.5132"},{"key":"1265_CR22","doi-asserted-by":"crossref","unstructured":"Tantawy MA, Weshahy SA, Wadie M, Rezk MR. Novel HPTLC densitometric methods for determination of tamsulosin HCl and tadalafil in their newly formulated dosage form: comparative study and green profile assessment. Biomed Chromatogr. 2020;34(8).","DOI":"10.1002\/bmc.4850"},{"key":"1265_CR23","doi-asserted-by":"crossref","unstructured":"Rezk MR, Monir HH, Marzouk HM. Spectrophotometric assessment of the brand new antiviral combination: Sofosbuvir and velpatasvir in their pure forms and pharmaceutical formulation. Spectrochim Acta Mol Biomol Spectrosc. 2019;213.","DOI":"10.1016\/j.saa.2019.01.058"},{"key":"1265_CR24","doi-asserted-by":"crossref","unstructured":"Variyar PS, Chatterjee S, Sharma A. Fundamentals and theory of HPTLC-Based separation. High-Performance Thin-Layer Chromatography (HPTLC). 2011;27\u201339. https:\/\/link.springer.com\/chapter\/10.1007\/978-3-642-14025-9_2","DOI":"10.1007\/978-3-642-14025-9_2"},{"key":"1265_CR25","unstructured":"United States Pharmacopeia and The National Formulary, Rockville MD. USA: USP 44-NF 39, U.S. Pharmacopeial Convention. 2021."},{"key":"1265_CR26","unstructured":"FDA. Validation of chromatographic methods. Center for Drug Evaluation and Research (CDER)., 1994."},{"key":"1265_CR27","unstructured":"ICH harmonized tripartite guideline. Validation of analytical procedures: text and methodology Q2 (R1). 2005."},{"key":"1265_CR28","unstructured":"Stahl M. Peak purity analysis in HPLC and CE using diode-array technology application. Agilent Technol. 2003;8."},{"key":"1265_CR29","doi-asserted-by":"crossref","unstructured":"Papadoyannis IN, Gika HG. Peak purity determination with a diode array detector. J Liq Chromatogr Relat Technol. 2004;27(6).","DOI":"10.1081\/JLC-120030180"},{"key":"1265_CR30","doi-asserted-by":"crossref","unstructured":"Wadie M, Abdel-Moety EM, Rezk MR, Marzouk HM. A novel eco-friendly HPLC method with dual detection modes for versatile quantification of dutasteride and silodosin in pharmaceutical formulation, dissolution testing and spiked human plasma. Microchem J. 2024;197.","DOI":"10.1016\/j.microc.2023.109753"},{"key":"1265_CR31","unstructured":"Williams RL, Adams WP, Poochikian G, Hauck WW. Content Uniformity and Dose Uniformity: Current Approaches, Statistical Analyses, and Presentation of an Alternative Approach, with Special Reference to Oral Inhalation and Nasal Drug Products. 2002."},{"key":"1265_CR32","unstructured":"Pharmacopoeial US, Convention. (905) Uniformity of dosage units. Stage 6 harmonization. 2011."},{"issue":"6","key":"1265_CR33","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.trac.2008.05.003","volume":"27","author":"S Armenta","year":"2008","unstructured":"Armenta S, Garrigues S, de la Guardia M. Green Analytical Chemistry. TrAC - Trends Anal Chem. 2008;27(6):497\u2013511.","journal-title":"TrAC - Trends Anal Chem"},{"key":"1265_CR34","doi-asserted-by":"crossref","unstructured":"Larsen C, Lundberg P, Tang S, R\u00e0fols-Rib\u00e9 J, Sandstr\u00f6m A, Mattias Lindh E et al. A tool for identifying green solvents for printed electronics. Nat Commun. 2021;12(1).","DOI":"10.1038\/s41467-021-24761-x"},{"issue":"13","key":"1265_CR35","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1039\/C6GC00611F","volume":"18","author":"CM Alder","year":"2016","unstructured":"Alder CM, Hayler JD, Henderson RK, Redman AM, Shukla L, Shuster LE, et al. Updating and further expanding GSK\u2019s solvent sustainability guide. Green Chem. 2016;18(13):3879\u201390.","journal-title":"Green Chem"},{"key":"1265_CR36","doi-asserted-by":"publisher","unstructured":"Koller G, Fischer U, Hungerb\u00fchler K. Assessing Safety, Health, and Environmental Impact Early during Process Development. Ind Eng Chem Res [Internet]. 2000 [cited 2023 Oct 6];39(4):960\u201372. https:\/\/doi.org\/10.1021\/ie990669i","DOI":"10.1021\/ie990669i"},{"issue":"9","key":"1265_CR37","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1039\/b617536h","volume":"9","author":"C Capello","year":"2007","unstructured":"Capello C, Fischer U, Hungerb\u00fchler K. What is a green solvent? A comprehensive framework for the environmental assessment of solvents. Green Chem. 2007;9(9):927\u201393.","journal-title":"Green Chem"},{"issue":"21","key":"1265_CR38","doi-asserted-by":"publisher","first-page":"8657","DOI":"10.1039\/D1GC02318G","volume":"23","author":"J P\u0142otka-Wasylka","year":"2021","unstructured":"P\u0142otka-Wasylka J, Wojnowski W. Complementary green analytical procedure index (ComplexGAPI) and software. Green Chem. 2021;23(21):8657\u201365.","journal-title":"Green Chem"},{"issue":"14","key":"1265_CR39","doi-asserted-by":"publisher","first-page":"10076","DOI":"10.1021\/acs.analchem.0c01887","volume":"92","author":"F Pena-Pereira","year":"2020","unstructured":"Pena-Pereira F, Wojnowski W, Tobiszewski M. AGREE - Analytical GREEnness Metric Approach and Software. Anal Chem. 2020;92(14):10076\u201382.","journal-title":"Anal Chem"},{"key":"1265_CR40","doi-asserted-by":"crossref","unstructured":"Sharaf YA, Abd El-Fattah MH, El-Sayed HM, Hassan SA. A solvent-free HPLC method for the simultaneous determination of Favipiravir and its hydrolytic degradation product. Sci Rep. 2023;13(1).","DOI":"10.1038\/s41598-023-45618-x"},{"key":"1265_CR41","doi-asserted-by":"crossref","unstructured":"Nowak PM, Wietecha-Pos\u0142uszny R, Pawliszyn J. White Analytical Chemistry: an approach to reconcile the principles of Green Analytical Chemistry and functionality. TrAC - Trends in Analytical Chemistry. Volume 138. Elsevier B.V.; 2021.","DOI":"10.1016\/j.trac.2021.116223"},{"key":"1265_CR42","doi-asserted-by":"crossref","unstructured":"Prajapati P, Salunkhe M, Pulusu VS, Shah S. Integrated Approach of White Analytical Chemistry and Analytical Quality by Design to multipurpose RP-HPLC method for synchronous estimation of multiple fixed-dose combinations of paracetamol. Chem Afr. 2024;7(3).","DOI":"10.1007\/s42250-023-00819-9"},{"key":"1265_CR43","doi-asserted-by":"crossref","unstructured":"Prajapati P, Patel M, Kansara Y, Shah P, Pulusu VS, Shah S, Green. LC-MS\/MS method for in-vivo pharmacokinetics of mirabegron-encapsulated nanostructured lipid carriers in rat plasma: integrating white analytical chemistry and analytical quality by design approach. Sustain Chem Pharm. 2024;39.","DOI":"10.1016\/j.scp.2024.101523"},{"key":"1265_CR44","doi-asserted-by":"crossref","unstructured":"Marzouk HM, El-Hanboushy S, Obaydo RH, Fayez YM, Abdelkawy M, Lotfy HM. Sustainable chromatographic quantitation of multi-antihypertensive medications: application on diverse combinations containing hydrochlorothiazide along with LC\u2013MS\/MS profiling of potential impurities: greenness and whiteness evaluation. BMC Chem. 2023;17(1).","DOI":"10.1186\/s13065-023-01015-z"},{"key":"1265_CR45","doi-asserted-by":"crossref","unstructured":"Marzouk HM, Gouda AS, Rezk MR, Abdel-Megied AM. Innovative eco-friendly stability-indicating HPLC-PDA method for simultaneous determination of the emerging antiviral drugs against COVID-19 infection molnupiravir and favipiravir; degradation kinetic studies along with LC-MS based structure elucidation. Microchem J. 2024;205.","DOI":"10.1016\/j.microc.2024.111197"}],"container-title":["BMC Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13065-024-01265-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13065-024-01265-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13065-024-01265-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T20:04:03Z","timestamp":1724789043000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcchem.biomedcentral.com\/articles\/10.1186\/s13065-024-01265-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1265"],"URL":"https:\/\/doi.org\/10.1186\/s13065-024-01265-5","relation":{},"ISSN":["2661-801X"],"issn-type":[{"value":"2661-801X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,27]]},"assertion":[{"value":"25 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"157"}}